Johnson & Johnson launches public welfare project for functional cure of blood tumors

Professor Liu Li said that with the deepening of the aging of the population, the incidence rate of multiple myeloma has increased year by year. The growth of treatment demand has promoted the progress of clinical diagnosis and treatment, and has made a series of gratifying achievements. 

“With the innovation of treatment methods, some patients have achieved complete remission or above after receiving standardized treatment, combined with autologous stem cell transplantation and consolidation therapy. The progression free survival period can reach about five years, approaching a state of functional cure,” Liu said. 

Huang Chen, president of Johnson & Johnson Innovative Pharmaceuticals China, gave the speech at the event ceremony.

When it comes to the original intention of initiating this project, Huang Chen, president of Johnson & Johnson Innovative Pharmaceuticals China, said that Johnson & Johnson has been deeply rooted in the field of oncology for 20 years, continuously providing multiple solutions for patients at different stages of the disease through product iteration, hoping to promote chronic management of multiple myeloma, lymphoma and other diseases, and give more patients the opportunity to move towards functional cure. 

Huang said that Johnson & Johnson will continue to work together with multiple parties to explore innovative cancer patient service models with Chinese characteristics, benefiting more patients and extending the 'road to cure' to more waiting families. 

The event also innovatively created the customized Eight Section Brocade Rehabilitation Exercise for blood tumor patients, allowing them to bring disease rehabilitation training into their daily lives. Through soft and coherent movements, it soothes the body and mind, enhances immunity, and helps with functional healing. 

The end.